FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309138838> ?p ?o ?g. }

• W4309138838 abstract "A bstract The human and canine renin-angiotensin-aldosterone-systems (RAAS) play a central role in the pathophysiology of congestive heart failure (CHF), justifying the use of angiotensin converting enzyme inhibitors inhibitors (ACEi) in this indication. Seminal studies in canine CHF had suggested that the pharmacological action of benazepril was relatively independent of doses > 0.25 mg/kg P.O, thereby providing a rationale for the European label dose of 0.25 mg/kg P.O q24h in dogs with cardiovascular diseases. However, most of these earlier studies on benazepril pharmacodynamics relied on measures of ACE activity – a sub-optimal endpoint to characterize the effect of benazepril on the RAAS. Nonlinear mixed-effects (NLME) modeling is an established framework for characterizing the effect of therapeutics on complex biological systems, such as the RAAS cascade. Importantly for therapeutic schedule optimization, one can use such a model to predict the outcomes of various hypothetical dosing schedules via simulation. The objectives of this study were (i) to expand on previous NLME modeling efforts of the dose-exposure-response relationship of benazepril on biomarkers of the RAAS which are relevant to CHF pathophysiology and disease prognosis {angiotensins I, II, III, IV, (1-7)} by using a quantitative systems pharmacology (QSP) modeling approach; and (ii) to develop a software implementation of the model capable of simulating clinical trials in benazepril in dogs bedside dose optimization. This study expands on previous modeling efforts to characterize the changes in RAAS pharmacodynamics in response to benazepril administration and showcase how QSP modeling can be used for efficient dose optimization of ACEis at the bedside. Our results suggest that 0.5 mg/kg PO q12h of benazepril produced the most robust reduction in AngII and upregulation of RAAS alternative pathway biomarkers. This model will eventually be expanded to include relevant clinical endpoints, which will be evaluated in an upcoming prospective trial in canine patients with CHF. A uthor S ummary Congestive heart failure (CHF) is a disease of the heart, common to both dogs and humans, where the heart is not healthy enough to pump blood around the body efficiently. Because the blood isn’t moving around the body as efficiently, it tends to get congested in various areas of the body and increases strain on the heart. Benazepril is a drug for CHF used in both dogs and humans to reduce congestion and improve the functioning of the cardiovascular system. Although benazepril is effective, there’s evidence that suggests the dosing could be improved if the therapeutic was further studied. In this experiment, we tested benazepril at several safe dosages in well-cared for and healthy dogs to collect data on the relationship between dose size, dosing frequency, and effect on the cardiovascular system. Using this data, we built computer models of benazepril to simulate many clinical trials. By studying these simulations, we were able to make several predictions about the optimal dosing schedule of benazepril in dogs. We’ve also built a web-app version of the computer model for veterinary researchers to use, modify, and study. This work also provides a platform and roadmap for optimizing benazepril dosages in human CHF." @default.
• W4309138838 created "2022-11-23" @default.
• W4309138838 creator A5000396447 @default.
• W4309138838 creator A5007815909 @default.
• W4309138838 creator A5014807506 @default.
• W4309138838 creator A5020391614 @default.
• W4309138838 creator A5031092581 @default.
• W4309138838 creator A5039909407 @default.
• W4309138838 creator A5079465597 @default.
• W4309138838 date "2022-11-16" @default.
• W4309138838 modified "2023-09-27" @default.
• W4309138838 title "<i>Breakthrough</i>: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Veterinary Cardiology" @default.
• W4309138838 cites W1869891936 @default.
• W4309138838 cites W1967716971 @default.
• W4309138838 cites W1988148376 @default.
• W4309138838 cites W1988559554 @default.
• W4309138838 cites W2023846978 @default.
• W4309138838 cites W2031829160 @default.
• W4309138838 cites W2033684886 @default.
• W4309138838 cites W2054238450 @default.
• W4309138838 cites W2086182043 @default.
• W4309138838 cites W2105095326 @default.
• W4309138838 cites W2133642143 @default.
• W4309138838 cites W2137241963 @default.
• W4309138838 cites W2143954917 @default.
• W4309138838 cites W2145434855 @default.
• W4309138838 cites W2146897448 @default.
• W4309138838 cites W2152136948 @default.
• W4309138838 cites W2160638998 @default.
• W4309138838 cites W2165634688 @default.
• W4309138838 cites W2166469889 @default.
• W4309138838 cites W2337855427 @default.
• W4309138838 cites W2915506231 @default.
• W4309138838 cites W2939525683 @default.
• W4309138838 cites W2992134502 @default.
• W4309138838 cites W3006701874 @default.
• W4309138838 cites W3007803872 @default.
• W4309138838 cites W3033591520 @default.
• W4309138838 cites W3187191459 @default.
• W4309138838 cites W4241359566 @default.
• W4309138838 doi "https://doi.org/10.1101/2022.11.14.516497" @default.
• W4309138838 hasPublicationYear "2022" @default.
• W4309138838 type Work @default.
• W4309138838 citedByCount "0" @default.
• W4309138838 crossrefType "posted-content" @default.
• W4309138838 hasAuthorship W4309138838A5000396447 @default.
• W4309138838 hasAuthorship W4309138838A5007815909 @default.
• W4309138838 hasAuthorship W4309138838A5014807506 @default.
• W4309138838 hasAuthorship W4309138838A5020391614 @default.
• W4309138838 hasAuthorship W4309138838A5031092581 @default.
• W4309138838 hasAuthorship W4309138838A5039909407 @default.
• W4309138838 hasAuthorship W4309138838A5079465597 @default.
• W4309138838 hasBestOaLocation W43091388381 @default.
• W4309138838 hasConcept C111113717 @default.
• W4309138838 hasConcept C112705442 @default.
• W4309138838 hasConcept C126322002 @default.
• W4309138838 hasConcept C2777288759 @default.
• W4309138838 hasConcept C2777363265 @default.
• W4309138838 hasConcept C2778198053 @default.
• W4309138838 hasConcept C71924100 @default.
• W4309138838 hasConcept C84393581 @default.
• W4309138838 hasConcept C98274493 @default.
• W4309138838 hasConceptScore W4309138838C111113717 @default.
• W4309138838 hasConceptScore W4309138838C112705442 @default.
• W4309138838 hasConceptScore W4309138838C126322002 @default.
• W4309138838 hasConceptScore W4309138838C2777288759 @default.
• W4309138838 hasConceptScore W4309138838C2777363265 @default.
• W4309138838 hasConceptScore W4309138838C2778198053 @default.
• W4309138838 hasConceptScore W4309138838C71924100 @default.
• W4309138838 hasConceptScore W4309138838C84393581 @default.
• W4309138838 hasConceptScore W4309138838C98274493 @default.
• W4309138838 hasLocation W43091388381 @default.
• W4309138838 hasOpenAccess W4309138838 @default.
• W4309138838 hasPrimaryLocation W43091388381 @default.
• W4309138838 hasRelatedWork W1979746426 @default.
• W4309138838 hasRelatedWork W1988935887 @default.
• W4309138838 hasRelatedWork W2021831895 @default.
• W4309138838 hasRelatedWork W2096040265 @default.
• W4309138838 hasRelatedWork W2152560731 @default.
• W4309138838 hasRelatedWork W2207503964 @default.
• W4309138838 hasRelatedWork W2899072855 @default.
• W4309138838 hasRelatedWork W2922882148 @default.
• W4309138838 hasRelatedWork W3021369409 @default.
• W4309138838 hasRelatedWork W2108030623 @default.
• W4309138838 isParatext "false" @default.
• W4309138838 isRetracted "false" @default.
• W4309138838 workType "article" @default.